MedTrace Logo

Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma

NCT04143425 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2024-05-14

No results posted yet for this study

Summary

This study aims to evaluate whether pre-treatment MRI can be used to predict treatment response for anti-angiogenic treatment in glioblastomas.

Conditions

  • Adult Glioblastoma
  • Magnetic Resonance Imaging
  • Bevacizimab

Interventions

DIAGNOSTIC_TEST

3-Tesla conventional magnetic resonance imaging

T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging

DIAGNOSTIC_TEST

Advanced imaging without contrast use

Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy

DIAGNOSTIC_TEST

Dynamic susceptibility contrast-weighted imaging

Cerebral blood volume and vessel architectural imaging parameters

Sponsors & Collaborators

  • Ho Sung Kim

    lead OTHER

Principal Investigators

  • Ho Sung Kim, M.D.,Ph.D. · Department of Radiology, Asan Medical Center

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-06
Primary Completion
2021-08-31
Completion
2022-11-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04143425 on ClinicalTrials.gov